Tetra Radar · FDA Approvals · Decision date
ONS-5010: FDA decision date
Outlook Therapeutics Inc (OTLK) · 29 July 2026
The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.
Source: 8-K of 16 June 2026
The FDA approved it on 24 July 2026.
The FDA approved Lytenava to treat patients with neovascular (wet) age-related macular degeneration.
Outlook Therapeutics Inc on Tetra Radar
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.